Cargando…

Therapeutic Effects of Naringin in Rheumatoid Arthritis: Network Pharmacology and Experimental Validation

Rheumatoid arthritis is a chronic autoimmune disease characterized by persistent hyperplasia of the synovial membrane and progressive erosion of articular cartilage. Disequilibrium between the proliferation and death of RA fibroblast-like synoviocytes (RA-FLSs) is the critical factor in progression...

Descripción completa

Detalles Bibliográficos
Autores principales: Aihaiti, Yirixiati, Song Cai, Yong, Tuerhong, Xiadiye, Ni Yang, Yan, Ma, Yao, Shi Zheng, Hai, Xu, Ke, Xu, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160516/
https://www.ncbi.nlm.nih.gov/pubmed/34054546
http://dx.doi.org/10.3389/fphar.2021.672054
_version_ 1783700302509113344
author Aihaiti, Yirixiati
Song Cai, Yong
Tuerhong, Xiadiye
Ni Yang, Yan
Ma, Yao
Shi Zheng, Hai
Xu, Ke
Xu, Peng
author_facet Aihaiti, Yirixiati
Song Cai, Yong
Tuerhong, Xiadiye
Ni Yang, Yan
Ma, Yao
Shi Zheng, Hai
Xu, Ke
Xu, Peng
author_sort Aihaiti, Yirixiati
collection PubMed
description Rheumatoid arthritis is a chronic autoimmune disease characterized by persistent hyperplasia of the synovial membrane and progressive erosion of articular cartilage. Disequilibrium between the proliferation and death of RA fibroblast-like synoviocytes (RA-FLSs) is the critical factor in progression of RA. Naringin has been reported to exert anti-inflammatory and antioxidant effect in acute and chronic animal models of RA. However, the therapeutic effect and underlying mechanisms of naringin in human RA-FLS remain unclear. Based on network pharmacology, the corresponding targets of naringin were identified using SwissTargetPrediction database, STITCH database, and Comparative Toxicogenomics Database. Deferentially expressed genes (DEGs) in RA were obtained from the GEO database. The protein–protein interaction (PPI) networks of intersected targets were constructed using the STRING database and visualized using Cytoscape. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed, and the pathways directly related to pathogenesis of RA were integrated manually. Further, in vitro studies were carried out based on network pharmacology. 99 target genes were intersected between targets of naringin and DEGs. The PPI network and topological analysis indicated that IL-6, MAPK8, MMP-9, TNF, and MAPK1 shared the highest centrality among all. GO analysis and KEGG analysis indicated that target genes were mostly enriched in (hsa05200) pathways in cancer, (hsa05161) hepatitis B, (hsa04380) osteoclast differentiation, (hsa04151) PI3K-Akt signaling pathway, and (hsa05142) Chagas disease (American trypanosomiasis). In vitro studies revealed that naringin exposure was found to promote apoptosis of RA-FLS, increased the activation of caspase-3, and increased the ratio of Bax/Bcl-2 in a dose-dependent manner. Furthermore, treatment of naringin attenuated the production of inflammatory cytokines and matrix metalloproteinases (MMPs) in TNF-ɑ–induced RA-FLS. Moreover, treatment of naringin inhibited the phosphorylation of Akt and ERK in RA-FLS. Network pharmacology provides a predicative strategy to investigate the therapeutic effects and mechanisms of herbs and compounds. Naringin inhibits inflammation and MMPs production and promotes apoptosis in RA-FLS via PI3K/Akt and MAPK/ERK signaling pathways.
format Online
Article
Text
id pubmed-8160516
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81605162021-05-29 Therapeutic Effects of Naringin in Rheumatoid Arthritis: Network Pharmacology and Experimental Validation Aihaiti, Yirixiati Song Cai, Yong Tuerhong, Xiadiye Ni Yang, Yan Ma, Yao Shi Zheng, Hai Xu, Ke Xu, Peng Front Pharmacol Pharmacology Rheumatoid arthritis is a chronic autoimmune disease characterized by persistent hyperplasia of the synovial membrane and progressive erosion of articular cartilage. Disequilibrium between the proliferation and death of RA fibroblast-like synoviocytes (RA-FLSs) is the critical factor in progression of RA. Naringin has been reported to exert anti-inflammatory and antioxidant effect in acute and chronic animal models of RA. However, the therapeutic effect and underlying mechanisms of naringin in human RA-FLS remain unclear. Based on network pharmacology, the corresponding targets of naringin were identified using SwissTargetPrediction database, STITCH database, and Comparative Toxicogenomics Database. Deferentially expressed genes (DEGs) in RA were obtained from the GEO database. The protein–protein interaction (PPI) networks of intersected targets were constructed using the STRING database and visualized using Cytoscape. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed, and the pathways directly related to pathogenesis of RA were integrated manually. Further, in vitro studies were carried out based on network pharmacology. 99 target genes were intersected between targets of naringin and DEGs. The PPI network and topological analysis indicated that IL-6, MAPK8, MMP-9, TNF, and MAPK1 shared the highest centrality among all. GO analysis and KEGG analysis indicated that target genes were mostly enriched in (hsa05200) pathways in cancer, (hsa05161) hepatitis B, (hsa04380) osteoclast differentiation, (hsa04151) PI3K-Akt signaling pathway, and (hsa05142) Chagas disease (American trypanosomiasis). In vitro studies revealed that naringin exposure was found to promote apoptosis of RA-FLS, increased the activation of caspase-3, and increased the ratio of Bax/Bcl-2 in a dose-dependent manner. Furthermore, treatment of naringin attenuated the production of inflammatory cytokines and matrix metalloproteinases (MMPs) in TNF-ɑ–induced RA-FLS. Moreover, treatment of naringin inhibited the phosphorylation of Akt and ERK in RA-FLS. Network pharmacology provides a predicative strategy to investigate the therapeutic effects and mechanisms of herbs and compounds. Naringin inhibits inflammation and MMPs production and promotes apoptosis in RA-FLS via PI3K/Akt and MAPK/ERK signaling pathways. Frontiers Media S.A. 2021-05-14 /pmc/articles/PMC8160516/ /pubmed/34054546 http://dx.doi.org/10.3389/fphar.2021.672054 Text en Copyright © 2021 Aihaiti, Song Cai, Tuerhong, Ni Yang, Ma, Shi Zheng, Xu and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Aihaiti, Yirixiati
Song Cai, Yong
Tuerhong, Xiadiye
Ni Yang, Yan
Ma, Yao
Shi Zheng, Hai
Xu, Ke
Xu, Peng
Therapeutic Effects of Naringin in Rheumatoid Arthritis: Network Pharmacology and Experimental Validation
title Therapeutic Effects of Naringin in Rheumatoid Arthritis: Network Pharmacology and Experimental Validation
title_full Therapeutic Effects of Naringin in Rheumatoid Arthritis: Network Pharmacology and Experimental Validation
title_fullStr Therapeutic Effects of Naringin in Rheumatoid Arthritis: Network Pharmacology and Experimental Validation
title_full_unstemmed Therapeutic Effects of Naringin in Rheumatoid Arthritis: Network Pharmacology and Experimental Validation
title_short Therapeutic Effects of Naringin in Rheumatoid Arthritis: Network Pharmacology and Experimental Validation
title_sort therapeutic effects of naringin in rheumatoid arthritis: network pharmacology and experimental validation
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160516/
https://www.ncbi.nlm.nih.gov/pubmed/34054546
http://dx.doi.org/10.3389/fphar.2021.672054
work_keys_str_mv AT aihaitiyirixiati therapeuticeffectsofnaringininrheumatoidarthritisnetworkpharmacologyandexperimentalvalidation
AT songcaiyong therapeuticeffectsofnaringininrheumatoidarthritisnetworkpharmacologyandexperimentalvalidation
AT tuerhongxiadiye therapeuticeffectsofnaringininrheumatoidarthritisnetworkpharmacologyandexperimentalvalidation
AT niyangyan therapeuticeffectsofnaringininrheumatoidarthritisnetworkpharmacologyandexperimentalvalidation
AT mayao therapeuticeffectsofnaringininrheumatoidarthritisnetworkpharmacologyandexperimentalvalidation
AT shizhenghai therapeuticeffectsofnaringininrheumatoidarthritisnetworkpharmacologyandexperimentalvalidation
AT xuke therapeuticeffectsofnaringininrheumatoidarthritisnetworkpharmacologyandexperimentalvalidation
AT xupeng therapeuticeffectsofnaringininrheumatoidarthritisnetworkpharmacologyandexperimentalvalidation